Management of HCC.
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal neoplasia, the management of which has significantly improved during the last few years. A better knowledge of the natural history of the tumor and the development of staging systems that stratify patients according to the characteristics of the tumor, the liver disease, and the performance status, such as the BCLC (Barcelona Clinic Liver Cancer) system, have led to a better prediction of prognosis and to a most appropriate treatment approach. Today curative therapies (resection, transplantation, ablation) can improve survival in patients diagnosed at an early HCC stage and offer a potential long-term cure. Patients with intermediate stage HCC benefit from chemoembolization and those diagnosed at advanced stage benefit from sorafenib, a multikinase inhibitor with antiangiogenic and antiproliferative effects. In this article we review the current management in HCC and the new advances in this field.
Barcelona Clinic Liver Cancer Group, Liver Unit, ICMDM, Hospital Clínic, IDIBAPS, University of Barcelona, Spain.
Carlos Rodríguez
CR
de Lope
Silvia
S
Tremosini
Alejandro
A
Forner
María
M
Reig
Jordi
J
Bruix
D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D055088:Early Detection of Cancer; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D016031:Liver Transplantation; D058990:Molecular Targeted Therapy